Paper39587352
The consequences of SARS-CoV-2 within-host persistence.
Sigal A and 2 others. Nat Rev Microbiol, 2025. Cited by 25 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The consequences of SARS-CoV-2 within-host persistence. Papers, record 39587352. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39587352
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| SARS-CoV-2 | Major topic |
| COVID-19 | Major topic |
| Humans | |
| Virus Replication | |
| Mutation | |
| Antibodies, Neutralizing |
Source PubMed
References223
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35,597,249 | Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. | Lancet Glob Health | 2022 | https://conductscience.org/library/papers/35597249 | PubMed |
| 2 | 32,017,770 | Interference with HIV infection of the first cell is essential for viral clearance at sub-optimal levels of drug inhibition. | PLoS Comput Biol | 2020 | https://conductscience.org/library/papers/32017770 | PubMed |
| 3 | 37,539,764 | The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future. | J Infect Dis | 2023 | https://conductscience.org/library/papers/37539764 | PubMed |
| 4 | 34,942,634 | Evolution of enhanced innate immune evasion by SARS-CoV-2. | Nature | 2022 | https://conductscience.org/library/papers/34942634 | PubMed |
| 5 | 38,663,423 | The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China. | Lancet Infect Dis | 2024 | https://conductscience.org/library/papers/38663423 | PubMed |
| 6 | 34,431,691 | Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment. | mSphere | 2021 | https://conductscience.org/library/papers/34431691 | PubMed |
| 7 | 36,007,063 | SARS-CoV-2 ORF6 disrupts innate immune signalling by inhibiting cellular mRNA export. | PLoS Pathog | 2022 | https://conductscience.org/library/papers/36007063 | PubMed |
| 8 | 35,996,593 | Recurrent SARS-CoV-2 mutations in immunodeficient patients. | Virus Evol | 2022 | https://conductscience.org/library/papers/35996593 | PubMed |
| 9 | 31,676,304 | Persistent Dengue Infection in an Immunosuppressed Patient Reveals the Roles of Humoral and Cellular Immune Responses in Virus Clearance. | Cell Host Microbe | 2019 | https://conductscience.org/library/papers/31676304 | PubMed |
| 10 | 34,796,242 | The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study. | Open Forum Infect Dis | 2021 | https://conductscience.org/library/papers/34796242 | PubMed |
| 11 | 37,270,625 | Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants. | Nat Commun | 2023 | https://conductscience.org/library/papers/37270625 | PubMed |
| 12 | 7,541,846 | Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. | J Virol | 1995 | https://conductscience.org/library/papers/7541846 | PubMed |
| 13 | 33,431,879 | Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). | Nat Commun | 2021 | https://conductscience.org/library/papers/33431879 | PubMed |
| 14 | 34,903,718 | Increased transmissibility of SARS-CoV-2 lineage B.1.1.7 by age and viral load. | Nat Commun | 2021 | https://conductscience.org/library/papers/34903718 | PubMed |
| 15 | 29,514,238 | Persistent High Burden of Advanced HIV Disease Among Patients Seeking Care in South Africa's National HIV Program: Data From a Nationwide Laboratory Cohort. | Clin Infect Dis | 2018 | https://conductscience.org/library/papers/29514238 | PubMed |
| 16 | 38,487,021 | B-cell-depleted patients with persistent SARS-CoV-2 infection: combination therapy or monotherapy? A real-world experience. | Front Med (Lausanne) | 2024 | https://conductscience.org/library/papers/38487021 | PubMed |
| 17 | 36,717,718 | Rebound HIV-1 in cerebrospinal fluid after antiviral therapy interruption is mainly clonally amplified R5 T cell-tropic virus. | Nat Microbiol | 2023 | https://conductscience.org/library/papers/36717718 | PubMed |
| 18 | 38,720,002 | An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution. | Nat Med | 2024 | https://conductscience.org/library/papers/38720002 | PubMed |
| 19 | 38,266,109 | SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency. | Sci Transl Med | 2024 | https://conductscience.org/library/papers/38266109 | PubMed |
| 20 | 36,517,603 | SARS-CoV-2 infection and persistence in the human body and brain at autopsy. | Nature | 2022 | https://conductscience.org/library/papers/36517603 | PubMed |
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,903,367 | Microbial PAMPs-PRR driven neuroimmune signaling in the development of post-infectious persistent pain. | Anesthesiol Perioper Sci | 2026 | https://conductscience.org/library/papers/42903367 | PubMed |
| 42,515,087 | NTD Remodeling in the SARS-CoV-2 BA.3.2 Variant May Influence Spike Stability and Immune Escape. | Pathogens | 2026 | https://conductscience.org/library/papers/42515087 | PubMed |
| 42,367,880 | SARS-CoV-2 saltational events are recurrent and trace to persistent human infections. | bioRxiv | 2026 | https://conductscience.org/library/papers/42367880 | PubMed |
| 42,145,722 | Intrahost viral evolution of SARS-CoV-2 infections in rheumatic versus hematological patients with severe iatrogenic immunosuppression. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42145722 | PubMed |
| 42,037,411 | Predictive modeling of immune escape and antigenic grouping of SARS-CoV-2 variants. | J Virol | 2026 | https://conductscience.org/library/papers/42037411 | PubMed |
| 41,915,390 | Postacute Sequelae Following Omicron COVID-19 in Patients With Cancer. | JAMA Netw Open | 2026 | https://conductscience.org/library/papers/41915390 | PubMed |
| 41,884,606 | Evolution and viral properties of the SARS-CoV-2 BA.3.2 subvariant. | Virus Evol | 2026 | https://conductscience.org/library/papers/41884606 | PubMed |
| 41,880,345 | The impact of viral and host factors on the influenza A virus transmission bottleneck. | PLoS Pathog | 2026 | https://conductscience.org/library/papers/41880345 | PubMed |
| 41,739,834 | Viral evolution during primary infection in immunocompromised hosts. | PLoS Comput Biol | 2026 | https://conductscience.org/library/papers/41739834 | PubMed |
| 41,688,712 | Host proteins associated with strong neutralizing SARS-CoV-2 antibody responses in a South African cohort. | Commun Med (Lond) | 2026 | https://conductscience.org/library/papers/41688712 | PubMed |
| 41,633,357 | Antibody escape drives emergence of diverse spike haplotypes resembling variants of concern in persistent SARS-CoV-2 infections. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/41633357 | PubMed |
| 41,629,286 | Inducible CD147 up-regulation boosts extended SARS-CoV-2 infection triggering severe COVID-19 independent of ACE2. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/41629286 | PubMed |
| 41,384,162 | Expanding the causes of Fever of Unknown Origin in immunocompromised patients: report of two cases highlighting the role of SARS-CoV-2. | Infez Med | 2025 | https://conductscience.org/library/papers/41384162 | PubMed |
| 41,157,582 | Insights into Persistent SARS-CoV-2 Reservoirs in Chronic Long COVID. | Viruses | 2025 | https://conductscience.org/library/papers/41157582 | PubMed |
| 41,090,722 | The Effect of Long-Term Betacoronavirus Infection on the Permeability of the Blood-Brain Barrier-In Vitro Model Studies. | Cells | 2025 | https://conductscience.org/library/papers/41090722 | PubMed |
| 41,031,289 | Phylogenetic meta-analysis of persistent SARS-CoV-2 infections in immunocompromised individuals highlights the challenges of robust evolutionary rate estimation caused by low genetic diversity. | Virus Evol | 2025 | https://conductscience.org/library/papers/41031289 | PubMed |
| 40,933,128 | Isolation of a SARS-CoV-2 strain from pediatric patients in South Korea: biologic and genetic characterization. | Front Microbiol | 2025 | https://conductscience.org/library/papers/40933128 | PubMed |
| 40,872,325 | Relationship Between Cell Surface Viral Glycoprotein Expression and Resistance of Parainfluenza Virus Persistently Infected Cells to Complement-Mediated Lysis. | Pathogens | 2025 | https://conductscience.org/library/papers/40872325 | PubMed |
| 40,721,817 | Perioperative and anesthetic considerations for post-acute sequelae of COVID (PASC)/long COVID. | Perioper Med (Lond) | 2025 | https://conductscience.org/library/papers/40721817 | PubMed |
| 40,695,836 | Hamsters with long COVID present distinct transcriptomic profiles associated with neurodegenerative processes in brainstem. | Nat Commun | 2025 | https://conductscience.org/library/papers/40695836 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39587352
GET https://conductscience.org/api/papers/v1/39587352/references?page=2